1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival

Byooviz Ranibizumab Biosimilar Approved; Company Reveals Launch Date Expectations

 
• By Dave Wallace

Samsung Bioepis has celebrated the FDA’s first ever approval of an ophthalmic biosimilar with its endorsement of the firm’s Byooviz ranibizumab rival to Lucentis. The firm has also signaled a surprising expected launch date in the US, as well as offering expectations for launch in Europe where the biosimilar was also recently approved.

OK Sign Eye Woman
The FDA has approved the Byooviz ranibizumab biosimilar to Lucentis • Source: Alamy

Samsung Bioepis has seen its Byooviz (ranibizumab-nuna) biosimilar to Genentech’s Lucentis approved by the US Food and Drug Administration, marking the agency’s first ever approval of a biosimilar with ophthalmic indications.

At the same time, the joint venture between Samsung Biologics and Biogen has revealed launch date expectations for the SB11 product, both in the US – where the firm indicated that a settlement with the originator means the biosimilar will not launch until June next year – as well as in Europe where it was also recently approved

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

More from Products